

(図2)。ANのある児ではALT値が高く、脂肪肝を有する可能性が高いことが示された(図3)。ANの有無で身長SDスコア(図4)、出生体重(図5)、二親等以内の糖尿病の家族歴の有無(図6)に有意差を認めなかった。

[結論]

ANをもつ単純性肥満児における臨床的特徴について検討したところ、肥満度50%以上の高度肥満、8歳以上の例でANの出現率が増加した。また、ANもつ児では脂肪肝を有する可能性が高い。今後、ANをもつ児でどの程度、糖尿病が発症するかどうか大きな問題であり、注意深い経過観察が必要と思われた。

[参考文献]

1. 村田光範. 乳幼児の肥満とやせの判定について.

治療 1998; 80: 169~175.

2. 杉原茂孝、村田光範. IV. 外来での慢性疾患児の管理 肥満 小児科臨床 1998; 51: 1491~1498.
3. Scott CR, Smith JM, Craddock MM, Pihoker C. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. *Pediatrics* 1997; 100:84-91.
4. Glaser NS. Non-insulin-dependent diabetes mellitus in childhood and adolescence. *Pediatr Clin North Am* 1997; 44:307-337.
6. Stuart CA, Gilkison CR, Smith MM, Bosma AM, Keenan BS, Nagamani M. Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus. *Clin Pediatr (Phila)* 1998; 37:73-79.

THE CLINICAL CHARACTERISTICS OF SIMPLE OBESE CHILDREN WITH ACANTHOSIS NIGRICANS

Shigetaka Sugihara, Ayako Ikezaki, Keiko Ito, Mitunori Murata

Department of Pediatrics, Tokyo Women's Medical University, Daini Hospital

[Aim] To examine the clinical characteristics of simple obesity with acanthosis nigricans (AN) in children and adolescents.

[Method] 90 patients (37 females, 53 males, age ranged 3-19 years) with simple obesity were analyzed. The age, relative body weight, serum ALT and family history in obese children with AN were compared with those without AN. [Result] 36 (40%) of 90 children with simple obesity had AN. There was not a significant difference in the prevalence of AN between both sexes. The prevalence of AN was significantly higher in children whose relative body weight is more than 50%, and in older children (>8 years old). There was positive correlation of AN with serum ALT level, but not with height SD score, birth weight, and family history of diabetes mellitus.

[Discussion] Recently, hyperinsulinemia has been suggested to become critical factor for the development of type 2 diabetes with obesity also in Japan by the change of the eating habits. AN is a clinical sign of hyperinsulinemia. We showed the high prevalence of AN in obese Japanese children especially in teenage. It may be very important to elucidate when and how type 2 diabetes develops in simple obese children with AN to establish the preventing method for the disease.

図1. Acanthosis nigricansと肥満度の関係




図2. Acanthosis nigricansと年齢の関係




図3. Acanthosis nigricansと肝酵素の関係




図4. Acanthosis nigricansと身長SDスコアの関係




図5. Acanthosis nigricansと出生体重の関係





図6. Acanthosis nigricansと糖尿病家族歴の関係



IV. 研究の成果の刊行に関する一覧表

1. Hotta M, Shibasaki T, Arai K, Demura H. Corticotropin-releasing factor receptor type 1 mediates emotional stress-induced inhibition of food intake and behavioral changes in rats. *Brain Res* 1999;823:221-225.
2. Makino S, Shibasaki T, Yamauchi N et al. Psychological stress increased corticotropin-releasing hormone mRNA and cotent in the central nucleus of the amygdala but not in the hypothalamic paraventricular nucleus in the rat. *Brain Res* 1999; 850: 136-143.
3. Hotta M, Fukuda I, Hizuka N, Shibasaki T, Takano K. The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa. *J Clin Endocrinol Metab* 2000; 85:200-206.
4. Kuriyama H, Hotta M, Wakabayashi I, Shibasaki T. A 6-day Intracerebroventricular infusion of the growth hormone-releasing peptide KP-102 stimulates food intake in both non-stressed and intermittently-stressed rats. *Neurosci Lett* in press (2000)
5. Ohata H, Suzuki K, Oki Y, Shibasaki T. Urocortin in the ventromedial hypothalamic nucleus acts as an inhibitor of feeding behavior in rats. *Brain Res* in press (2000)
6. Wakabayashi I, Sugihara H, Shibasaki T. Growth hormone secretagogue influences feeding behavior in experimental animals. In: Ghigo E, et al editors. Growth Hormone Secretagogues. *Elsevier Science B.V.* , 1999; 279-284.
7. Nakayama M, Yasue H, Yoshimura M et al. A T-786-C mutation in the 5' -flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. *Circulation* 99; 2864-2870, 1999.
8. Ogawa Y, Masuzaki H, Nakao K. Clinical implication of leptin, the obese gene product. *Intern. Med.* 1999; 38: 210-212.
9. Mori K, Ogawa Y, Ebihara K, et al. Isolation and characterization of CA XIV, a novel membrane-bound carbonic anhydrase from mouse kidney. *J. Biol. Chem.* 1999; 274: 15701-15705.
10. Kuwahara K, Saito Y, Nakagawa O, et al. The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes: Possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. *FEBS Lett.* 1999; 452: 314-318.
11. Chin K, Shimizu K, Nakamura T et al. Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. *Circulation* 1999; 100: 706-712.

12. Masuzaki H, Ogawa Y, Aizawa-Abe M et al. Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal *yellow agouti* mutation: Usefulness of leptin for the treatment of obesity-associated diabetes. *Diabetes* 1999; 48: 1615-1622.
13. Satoh N, Ogawa Y, Katsuura G et al. Sympathetic activation of leptin via the ventromedial hypothalamus: Leptin-induced increase in catecholamine secretion. *Diabetes* 1999; 48: 1787-1793.
14. Ogawa Y, Masuzaki H, Hosoda K et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. *Diabetes* 1999; 48: 1822-1829.
15. Ebihara K, Ogawa Y, Katsuura G et al. Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. *Diabetes* 1999; 48: 2028-2033.
16. Shintani M, Nishimura H, Akamizu T, et al. Thyrotropin decreases leptin production in rat adipocytes. *Metabolism* 1999; 48: 1570-1574.
17. Shintani M, Nishimura H, Yonemitsu S et al. Down-regulation of leptin by free fatty acids in rat adipocytes: Effects of triacsin C, palmitate and 2-bromopalmitate. *Metabolism* 2000; 49: 326-330.
18. Yamamoto Y, Yoshimasa Y, Koh M et al. Constitutively active mitogen-activated protein kinase increases GLUT1 expression and recruits both GLUT1 and GLUT4 at the cell surface in 3T3-L1 adipocytes. *Diabetes* 2000; 49: 332-339.
19. Yura S, Ogawa Y, Sagawa N et al. Accelerated puberty and late-onset hypothalamic hypogonadism in female transgenic skinny mice overexpressing leptin. *J. Clin. Invest.* 2000; 105: 749-755.
20. Ogawa Y, Sagawa N, Masuzaki H et al. Leptin, a novel placenta-derived hormone in humans. In: G. Ailhaud & B. Guy-Grand editor. *Progress in Obesity Research: 8*, London: John Libbey & Company Ltd., 1999; 71-75.
21. Ogawa Y, Masuzaki H, Sagawa N, Nakao K. Leptin as an adipocyte- and nonadipocyte-derived hormone. In: G.A. Bray & D.H. Ryan editor. *Pennington Center Nutrition Series: 9, Nutrition, Genetics, and Obesity*, Louisiana: Louisiana State University Press., 1999; 147-155.
22. Nakao K, Ogawa Y, Masuzaki H, et al. Potential usefulness of leptin for the treatment of diabetes. In: H. Imura, M. Kasuga, and K. Nakao editor. *Common Diseases: Genetic and Pathogenic Aspects of Multifactorial Diseases*, Amsterdam: Elsevier Science B.V., 1999; 21-30.

23. Masaki T, Yoshimatsu H, Chiba S, et al. Tumor necrosis factor- α regulates in vivo expression of the rat UCP family differentially. *BBA* 1999; 1436: 585-592.
24. Masaki T, Yoshimatsu H, Kakuma T, et al. Induction of rat uncoupling protein-2 gene treated with tumour necrosis factor alpha *in vivo*. *Eur J Clin Invest* 1999; 29: 76-82.
25. Kang M, Yoshimatsu H, Kurokawa M, Ogawa R, Sakata T, . Prostaglandin E2 mediates activation of hypothalamic histamine by interleukin-1 β in rats. *Proc Soc Exp Biol Med* 1999; 220: 88-93.
26. Hidaka S, Kakuma T, Yoshimatsu H, Sakino H, Fukuchi S, Sakata T, . Streptozotocin treatment upregulates uncoupling protein 3 expression in the rat heart. *Diabetes* 1999; 48: 430-435.
27. Masaki T, Yoshimatsu H, Chiba S, Kurokawa M, Sakata T, . Up-regulation of uterine UCP2 and UCP3 in pregnant rats. *BBA* 1999; 1440: 81-85.
28. Yoshimatsu H, Itateyama E, Kondou S, et al. Hypothalamic neuronal histamine as a target of leptin in feeding behavior. *Diabetes* 1999; 48: 2286-2291.
29. Teshima Y, Saikawa T, Yonemochi H, Hidaka S, Yoshimatsu H, Sakata T,. Alteration of heart uncoupling protein-2 mRNA regulated by sympathetic nerve and triiodothyronine during postnatal period In rat. *BBA* 1999; 1448: 409-415.
30. Sakata T, Sunaga K, Yoshimatsu H,. Recuperative effectiveness of Korean red ginseng in unidentified multi-complaints of patients with and without emotional disturbance. *Proceeding of 99 Korea-Japan Ginseng Symposium* 1999; 32-34.
31. Sakata T, Yoshimatsu H, Kurokawa M,. Molecular approaches to energy metabolism regulates by brain histamine. *Prog Obes Res* 1999; 8: 299-303.
32. Sakata T, Yoshimatsu H, Kurokawa M,. Histamine neuron-driven energy metabolism modulated by leptin. In : Yamashita H, Funder JW, Verbalis JG, Ueta Y, Endo Y, editor. *Control Mechanisms of stress and Emotion: Neuroendocrine- Based Studies*. Amsterdam: Elsevier, 1999; 165-172.
33. Sakurai T. Orexins and orexin receptors: implication in feeding behavior. *Reg. Peptides. Behavior Regulatory Peptides* 1999; 85: 25-30.
34. Yamanaka A, Sakurai T, Katsumoto T, Yanagisawa M, Goto K. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. *Brain Res.* 1999; 849: 248-252.
35. Kuni K, Yamanaka A, Nambu T, Matsuzaki I, Goto K, Sakurai T. Orexins regulate drinking behaviour. *Brain Res.* 1999; 842: 256-261.

36. Shibahara M, Sakurai T, Namubu T, Takenouchi T, Iwasa H, Egashira S, Ihara M, Goto K. Structure, tissue distribution, pharmacological characterization of *Xenopus* orexins. *Peptides*. 1999; 20(10): 1169-76.
37. Sakurai T, Moriguchi T, Furuya K, Kajiwara N, Nakamura T, Yanagisawa M, Goto K. Structure and function of human prepro-orexin gene. *J. Biol. Chem.* 1999; 274: 17771-17776.
38. Nambu T, Sakurai T, Muzukami K, Hosoya Y, Yanagisawa M, Goto K. Distribution of Orexin Neurons in the Adult Rat. *Brain Res.* 1999; 827: 243-260.
39. Moriguchi T, Sakurai T, Nambu T, Yanagisawa M, Goto K. Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced hypoglycemia. *Neurosci. Lett.* 1999; 264: 101-104.
40. Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S, Kangwa K, Sakurai T, Yanagisawa M, Nakazato M. Orexins, novel orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. *Proc. Natl. Acad. Sci. USA* 1999; 96: 748-753.
41. 桜井武、摂食行動の制御機構におけるオレキシンの役割 *ホルモンと臨床* 1999; 47: 567-573.
42. 桜井武、オレキシンの同定と生理作用の解析 *肥満研究* 1999; 46-48.
43. 桜井武、オレキシンの同定とその生理作用の解析 *血管* 1999; 22: 119-123.
44. 桜井武、摂食行動の制御機構におけるオレキシンの役割 *医学のあゆみ* 1999; 12. 13: 1085-1089.
45. Masuzaki H, Ogawa Y, Aizawa-Abe M et al. Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation - usefulness of leptin for the treatment of obesity-associated diabetes -. *Diabetes* 1999; 48: 1615-1622.
46. Satoh N, Ogawa Y, Katsuura G et al. Sympathetic activation of leptin via the ventromedial hypothalamus - leptin-induced increase in catecholamine secretion -. *Diabetes* 1999; 48: 1787-1793.
47. Ogawa Y, Masuzaki H, Hosoda K et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. *Diabetes* 1999; 48: 1822-1829.
48. Tanaka T, Itoh H, Doi K et al. Down regulation of peroxisome proliferator-activated receptor gamma expression by inflammatory cytokines and its reversal by thiazolidinediones. *Diabetologia* 1999; 42(6): 702-710.
49. Yamamoto Y, Yoshimasa Y, Koh M et al. Constitutive active mitogen-activated protein kinase increases GLUT1 expression and recruits both GLUT1 and GLUT4 surface in 3T3-

L1 adipocytes. *Diabetes* 2000; 49 : 332-339.

50. 溝口初枝, 増田彰則, 穂満直子, 村永鉄郎, 前田博子, 野添新一 心身医学 1999 ; 39 : 5
日本心身医学会 摂食障害患者に対するチーム医療と予後の関係
51. 胸元孝夫, 増田彰則, 成尾鉄朗, 添嶋裕嗣, 野添新一, 古賀靖之 行動療法研究 1999 ; 25 : 1
早期行動介入が奏功した神経性食欲不振症の姉妹例
-Broken Family を背景に発症した症例の検討-
52. 野添新一, 中山孝史 精神医学レビュー No.32 食の精神医学 1999 ; 91-98 摂食障害の入院
による行動治療法的治療
53. 成尾鉄朗, 野添新一 治療 1999 ; 81(7) : 136-137
神経性食欲不振症患者における前頭葉の局所脳血流低下と臨床病態との関連について
54. 野添新一 心身医学 日本醫事新報 別冊 2000 第 3956 号
55. Nakai Y, Hamagaki S, Kato S, Seino Y, Takagi R, Kurimoto F. Leptin in women with
eating disorders. *Metabolism* 1999 ; 48 : 217-220.
56. Nakai Y, Hamagaki S, Takagi R, Taniguchi A, Kurimoto F. Plasma concentrations of
tumor necrosis factor- α (TNF- α) and soluble TNF receptors in patients with anorexia
nervosa. *J Clin Endocrinol Metab* 1999 ; 84 : 1226-1228.
57. Nakai Y, Hamagaki S, Kato S, Seino Y, Takagi R, Kurimoto F. Role of leptin in women
with eating disorders. *Int J Eating Disorders* 1999 ; 26 : 29-35.
58. 中井義勝, 夏井耕之, 岡野五郎 摂食障害発症の成立過程について. *思春期学* 1999 ; 17 : 46-51.
59. 中井義勝, 濱垣誠司, 高木隆郎, 栗本文彦 神経性無食欲症と腫瘍壊死因子- α (TNF- α). *精神
医学* 1999 ; 41 : 501-504.
60. 中井義勝 摂食障害における社会・文化的背景について. *精神医学レビュー No.32 食の精
神医学*. 野上芳美, 竹中秀夫編. ライフ・サイエンス, 1999:109-113.
61. 中井義勝, 摂食障害の疫学. *心療内科* 2000; 4 : 1-9.
62. 中井義勝, 濱垣誠司, 高木隆郎, 栗本文彦. 神経性大食症と腫瘍壊死因子- α (TNF- α). *精神医
学* 2000 ; 42 : 141-144.
63. 久保木富房, 編 佐々木直, 中野弘一, 筒井末春ら「知っておきたい拒食症・過食症の新たな診
療」 真興交易医書出版部 2000; 13-25.
64. 久保木富房, 宮坂菜穂子 共著 「拒食症の病態生理と診断・治療」 真興交易医書出版部 2000
65. Takii M, Komaki G, Uchigata Y, Maeda M, Omori Y, Kubo C. Differences between bulimia
nervosa and binge-eating disorder in females with type 1 diabetes: The important role of
insulin omission *Journal of Psychosoma Res.* 1999; 47: 221-231.
66. 瀧井正人, 久保千春 強迫性の強い神経食欲不振症遷延例の治療—「強迫的防衛」への治療介入
—

- 久保木富房、編 知っておきたい拒食症・過食症の新たな診療 真興交易医書出版部 2000; 40-51.
67. Matsuoka H, Sato K, Sugihara S, Murata M. Bone maturation reflects the secular trend in growth. *Horm Res*, 1999; 52: 125-130.
68. Matsuoka H, Shamoto N, Kikuoka N, Sugihara S, Murata M. Changes in leptin and testosterone levels in a girl with congenital adrenal hyperplasia during hydrocortisone therapy a case report. *Pediatrics International*, 2000 (in press).
69. 平田直子、杉原茂孝、村田光範 幼児の性別、年齢別、身長別、標準体重に基づく新しいエネルギー所要量の検討. *日本小児栄養消化器病学会雑誌* 2000 ; 14 : 6-11.
70. 伊藤けい子、村田光範 肥満2. 疫学と肥満の判定基準、子どもと生活習慣病 *小児科臨床* 1999; 52: 1182-1193.
71. 村田光範 高脂血症、子どもと生活習慣病 *小児科臨床* 1999; 52: 1271-1279.
72. 杉原茂孝 糖尿病 3. 糖尿病と健康障害、子どもと生活習慣病、*小児科臨床* 1999; 52: 1316-1320.

V. 平成 11 年度研究者名簿

中枢性摂食異常症に関する調査研究

区 分	氏 名	所 属	職 名
主任研究者	中 尾 一 和	京都大学大学院医学研究科臨床病態医科学	教 授
分担研究者	久 保 木 富 房	東京大学医学部心療内科	教 授
	桜 井 武	筑波大学基礎医学系	助 教 授
	芝 崎 保	日本医科大学生理学第二	教 授
	中 井 義 勝	京都大学医療技術短期大学部	教 授
	久 保 千 春	九州大学医学部心療内科	教 授
	野 添 新 一	鹿児島大学医学部附属病院心身医療科	教 授
	坂 田 利 家	大分医科大学医学部第一内科	教 授
	村 田 光 範	東京女子医科大学附属第二病院小児科	教 授
	葛 谷 英 嗣	国立京都病院	副 院 長
	細 田 公 則	京都大学大学院人間・環境学研究科	助 手
	小 川 佳 宏	京都大学大学院医学研究科臨床病態医科学	助 手
事 務 局	吉 政 康 直	京都大学大学院医学研究科臨床病態医科学 京都市左京区聖護院川原町 54 TEL(075)751-3172 FAX(075)771-9452	講 師

厚生省特定疾患対策研究事業中枢性摂食異常症
平成 11 年度研究報告書

発行者 厚生省特定疾患対策研究事業中枢性摂食異常症
主任研究者 中 尾 一 和

(連絡先) 〒606-8507

京都市左京区聖護院川原町 54

京都大学大学院医学研究科臨床病態医科学講座
第 2 内科

TEL: 075-751-4345 FAX: 075-771-9452